AHA Scientific Sessions 2026 Abstract · Nov 2, 2026
Comparative Effects of Lipoprotein(a)-Targeted and Lipid-Modifying Therapies on Percent Change in Lipoprotein(a)
By Tanriverdi LH, Tas Y, Dogan MM et al.
Background: Elevated lipoprotein(a) [Lp(a)] is an independent and causal risk factor for atherosclerotic cardiovascular disease. While novel Lp(a)-targeted therapies have demonstrated substantial reductions in circulating Lp(a) levels, several established lipid-modifying therapies have also been reported to influence Lp(a) concentrations to varying degrees. However, the magnitude of Lp(a) reduction achieved by these therapies has not been comprehensively compared across randomized controlled trials. Hypothesis: To compare Lp(a)-targeted therapies on percentage reductions in Lp(a) in comparison to available non-Lp(a)-targeted lipid-modifying therapies. Methods: We performed a random-effects meta-analysis of randomized controlled trials (RCTs) evaluating percent change in Lp(a) from baseline. Mean differences (MDs) with 95% confidence intervals (CIs) were pooled using the R meta package. Agents were grouped by intervention class, and subgroup analyses were explored according to primary versus secondary prevention populations. Results: Twenty-three RCTs were included with 8538 participants. Overall, active therapy significantly reduced Lp(a) compared with control (MD, –37.28%; 95% CI, –50.50 to –24.06; p<0.0001), although heterogeneity was substantial (I ² =99.1%). The greatest reductions were observed with olpasiran (MD, –93.48%; 95% CI, –110.55 to –76.42), lepodisiran (MD, –78.39%; 95% CI, –94.40 to –62.37), zerlasiran (MD, –76.94%; 95% CI, –88.21 to –65.66), and pelacarsen (MD, –66.00%; 95% CI, –86.66 to –45.34). Muvalaplin also reduced Lp(a) (MD, –47.83%; 95% CI, –67.18 to –28.48). Among non-Lp(a)-targeted therapies, obicetrapib produced a moderate reduction (MD, –40.74%; 95% CI, –49.50 to –31.98), whereas inclisiran produced a smaller but significant reduction (MD, –21.96%; 95% CI, –26.70 to –17.21). Ezetimibe showed no significant effect on Lp(a) (MD, 1.20%; 95% CI, –3.04 to 5.44). In prevention-stratified analyses, findings remained directionally consistent, with larger reductions observed for Lp(a)-targeted agents than for established lipid-modifying therapies. Conclusions: Lp(a)-targeted agents achieved the largest reductions in Lp(a), whereas obicetrapib and inclisiran showed more modest effects and ezetimibe showed no meaningful reduction. These findings support the distinct pharmacologic role of emerging Lp(a)-targeted therapies and provide comparative context for interpreting Lp(a) changes with broader lipid-lowering agents. The final comprehensive meta-analysis, including PCSK9 monoclonal antibodies and oral PCSK9 inhibitors, will be presented at the AHA Scientific Sessions 2026.